| Sonstiges: |
- Nachgewiesen in: USPTO Patent Applications
- Sprachen: English
- Document Number: 20080096873
- Publication Date: April 24, 2008
- Appl. No: 11/960045
- Application Filed: December 19, 2007
- Claim: 1. A compound of the formula (II) [chemical expression included] or a pharmaceutically acceptable salt thereof, wherein R9, R12 and R14 are H; or two of R9, R12 and R14 are H; and the remaining of R9, R12 and R14 is (a) —NH2, (b) —NHR6, (c) —NR6R7, (d) —N(CO)R6, (e) —N(CS)R6, or (f) —NO2; R10 is a group R3; R11 is a group R1; in which each of R1 and R3, independently, is: (a) H (b) C1-6 alkyl, (c) C1-6 alkoxy, (d) straight or branched C1-6 hydroxyalkyl, (e) straight or branched C1-6 alkylhalides; or (f) a group Ar; Ar is (a) phenyl, (b) 1-naphthyl, (c) 2-naphthyl, (d) benzyl, (e) cinnamoyl, (f) a 5 to 7-membered, partially or completely saturated, heterocyclic ring containing 1 to 4 heteroatoms, selected from oxygen, nitrogen and sulfur, or (g) a bicyclic ring system consisting of two heterocyclic rings as defined under (f), or a bicyclic ring system consisting of one benzene ring and one heterocyclic ring as defined under (f); alternatively, R1 and R3 are linked to form a group (CH2)2O, (CH2)4O, or (CH2)3-5 in formula (Ib); optionally, the group Ar is substituted with (a) Y, or (b) a 5 to 7-membered, partially or completely saturated, heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur; Y is (a) H, (b) halogen, (c) C1-6 alkyl, (d) CF3, (e) hydroxy, (f) C1-6 alkoxy, (g) C1-4 alkenyl; (h) phenyl; (i) phenoxy, (j) benzyloxy, (k) benzoyl, (l) OCF3, (m) CN, (n) straight or branched C1-6 hydroxyalkyl, (o) straight or branched C1-6 alkylhalides, (p) NH2, (q) NHR6, (r) NR6R7, (s) NO2, (t) —CONR6R7, (u) NHSO2R6, (v) NR6COR7, (x) SO2NR6R7, (z) —C(═O)R6, (aa) —CO2R6, or (ab) S(O)nR6; wherein n is 0, 1, 2 or 3; R13 is (a) homopiperazine, (b) methylhomopiperazine, or (c) a group R5; and R5 is [chemical expression included] R6 and R7 are independently (a) H, (b) C1-6 alkyl, (c) C3-7 cycloalkyl, or (d) Ar, as defined above for R1; alternatively, R6 and R7 are linked to form a group (CH2)2O, (CH2)4O or (CH2)3-5; R8 is (a) H, or (b) C1-6 alkyl.
- Claim: 2. A compound according to claim 1 wherein R13 is (a) homopiperazine, (b) methylhomopiperazine, with the proviso that only one of R9, R12 and R14 is —NH2, —NHR6, —NR6R7, —N(CO)R6, —N(CS)R6, —NO2; the other ones are H.
- Claim: 3. A compound according to claim 1, which is the compound 4-chloro-N-[5-(4-methyl-1,4-diazepan-1-yl)-2-nitrophenyl]benzenesulfonamide, N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[2-amino-5-(4-methyl-1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-nitro-5-(piperazinyl)phenyl]benzenesulfonamide, or N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide.
- Claim: 4. A process for the preparation of a compound of claim 1 comprising: (a) introduction of a cyclic diamine into a halogen and nitro substituted benzene under mild and basic conditions; (b) reduction of the nitro to a corresponding amine; (c) selective introduction of a sulfonylamide group by a sulphonylchloride reacting with the amine; (d) introduction of a sulfonylanimo group by an aromatic nucleophilic substitution reaction.
- Claim: 5. A pharmaceutical formulation containing a compound of claim 1 as an active ingredient, in combination with a pharmaceutically acceptable diluent or carrier.
- Claim: 6. A method for the treatment or prophylaxis of obesity, or disorders of the central nervous system, comprising administering to a mammal, in need of such treatment an effective amount of a compound of claim 1.
- Current U.S. Class: 514221/000
- Current International Class: 61; 61; 61; 07; 07; 61; 61
|
